Cover Image
市場調查報告書

子宮頸癌的全球市場 2015-2019年

Global Cervical Cancer Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 339611
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
子宮頸癌的全球市場 2015-2019年 Global Cervical Cancer Market 2015-2019
出版日期: 2015年09月09日 內容資訊: 英文 70 Pages
簡介

全球子宮頸癌市場,預計從2014年到2019年以4.87%的年複合成長率成長。

本報告提供全球子宮頸癌市場相關分析、市場概要和結構、市場規模趨勢 、各地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商的產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

第5章 疾病概要

  • 疾病的理解
  • 風險要素
  • 徵兆、症狀
  • 篩檢
  • 診斷
  • 分期
  • 治療
  • 流行病學

第6章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第7章 市場區隔:各用途

  • 全球預防疫苗市場
  • 全球治療藥市場

第8章 市場區隔:各治療類型

  • 全球子宮頸癌治療市場:各治療類型
  • 化療
  • 標靶治療
  • 人類乳突病毒(HPV)疫苗

第9章 地區區分

第10章 領導品牌分析

  • Gardasil,Gardasil9及Cervarix 比較研究

第11章 開發平台的組合

第12章 市場成長的促進要素

第13章 促進要素的影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 業者情勢

  • 競爭情形
  • 市場分析
  • 其他卓越供應商

第18章 主要供應商分析

  • GSK
  • F. Hoffmann-La Roche
  • Merck

第19章 附錄

第20章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR7066

About cervical cancer

Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer. Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue. Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas.

Technavio's analysts forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.

Technavio's report, Global Cervical Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck

Other Prominent Vendors

  • Advaxis Immunotherapies
  • Bionor Pharma
  • Dendreon Corporation
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • Otsuka Pharmaceuticals
  • Profectus Biosciences
  • Virometix
  • Zeria Pharmaceuticals

Key market driver

  • Increase in incidence rate
  • For a full, detailed list, view our report

Key market challenge

  • Adverse effects of drugs and vaccines
  • For a full, detailed list, view our report

Key market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Screening
  • Diagnosis
  • Staging
  • Treatment
  • Epidemiology

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by application

  • Global prophylactic vaccines market
  • Global therapeutic drugs market

PART 08: Market segmentation by type of therapy

  • Global cervical cancer therapeutics market by type of therapy
  • Chemotherapy
  • Targeted therapy
  • HPV vaccines

PART 09: Geographical segmentation

PART 10: Key brand analysis

  • Comparative study between Gardasil, Gardasil 9, and Cervarix

PART 11: Pipeline portfolio

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • GSK
  • F. Hoffmann-La Roche
  • Merck

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Risk factors for cervical cancer
  • Exhibit 02: Screening tests for cervical cancer
  • Exhibit 03: Diagnostic tests for cervical cancer
  • Exhibit 04: FIGO staging for cervical cancer
  • Exhibit 05: Management of cervical cancer
  • Exhibit 06: Chemotherapy for treatment of cervical cancer
  • Exhibit 07: Cervical cancer treatment algorithm
  • Exhibit 08: Countries with highest cervical cancer rates
  • Exhibit 09: Cervical cancer deaths by age group in the US 2008-2012
  • Exhibit 10: Age-specific incidence rates of cervical cancer in the US by race 2008-2012
  • Exhibit 11: Age-specific mortality rates of cervical cancer of women in the US by race 2008-2012
  • Exhibit 12: Mortality rates of cervical cancer of women in the US by race 2008-2012
  • Exhibit 13: Average number of cervical cancer deaths in EU 2010-2012
  • Exhibit 14: Cervical cancer incidence and mortality rates in EU 2007-2011
  • Exhibit 15: Global cervical cancer therapeutics market 2014-2019 ($ billions)
  • Exhibit 16: Global cervical cancer therapeutics market segmentation by application
  • Exhibit 17: Global prophylactic vaccines market 2014-2019 ($ millions)
  • Exhibit 18: Global therapeutic drugs market 2014-2019 ($ millions)
  • Exhibit 19: Segmentation of global cervical cancer therapeutics market 2014
  • Exhibit 20: Global cervical cancer therapeutics market by type of therapy
  • Exhibit 21: Segmentation of global cervical cancer therapeutics market by region 2014
  • Exhibit 22: Global cervical cancer vaccines market: Comparison of major brands
  • Exhibit 23: Gardasil, Gardasil 9, and Cervarix: A comparative study
  • Exhibit 24: Key late-stage HPV vaccines for cervical cancer
  • Exhibit 25: Drivers of global cervical cancer therapeutics market
  • Exhibit 26: Impact of drivers
  • Exhibit 27: Challenges of global cervical cancer therapeutics market
  • Exhibit 28: Impact of drivers and challenges
  • Exhibit 29: Trends of global cervical cancer therapeutics market
  • Exhibit 30: Gardasil: Global revenue and growth rate 2011-2014
  • Exhibit 31: Merck: Key takeaways
  • Exhibit 32: Cervarix: Global revenue and growth rate 2012-2014
  • Exhibit 33: GSK: Key takeaways
  • Exhibit 34: F. Hoffman-La Roche: Key takeaways
Back to Top